ARTICLE | Politics & Policy

PFMD outlines priorities, invites payers and regulators

October 24, 2015 1:49 AM UTC

The Patient Focused Medicines Development initiative outlined its priorities and invited other stakeholders including payers and regulators to join.

PFMD is a public-private partnership between industry and patient groups that was launched in May. Founding members include Amgen Inc. (NASDAQ:AMGN), AstraZeneca plc (LSE:AZN; NYSE:AZN), UCB Group (Euronext:UCB), GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Pfizer Inc. (NYSE:PFE), Merck Sharp & Dohme Corp. (MSD), the National Health Council, the Parkinson's Disease Foundation, the European Patients' Academy on Therapeutic Innovation (EUPATI), the European Patients' Forum, the Society for Participatory Medicine, the Cancer101 Foundation, and the Clinical Trials Transformation Initiative (CTTI). MSD is a subsidiary of Merck & Co. Inc. (NYSE:MRK) (see BioCentury, Sept. 7). ...